Our Team

Andrew Levin joined RA Capital Management in 2015 and is a Partner and Managing Director on the Investment Team and spearheads a drug discovery effort that has led to the formation of several new companies. Prior to joining RA Capital, Andrew was Vice President at H.I.G. BioVentures. Previously, he served as the Director of Pharmaceutical Sciences at the Clinton Health Access Initiative. Andrew holds a BSE in Mechanical Engineering from Princeton University, a PhD in Biomedical Engineering from the Massachusetts Institute of Technology, and an MD from Harvard Medical School.

Charles joined SV Health Investors in 2018 and is a Vice President in the Biotech team. His role spans from formation to funding of companies that develop transformational new medicines, with a broad focus from new company creation to later stage public and private opportunities. In addition to Imbria, Charles serves on the Board of Mestag Therapeutics, which he incubated and launched. Charles is also Board Observer at Autifony Therapeutics, EnaraBio and Pulmocide. Prior to joining SV Health, Charles qualified as an ACA after three years at Deloitte, with a focus on Life Sciences’ clients including SV Health portfolio companies. Charles holds a MSci Human Genetics, University College London (UCL) and is a chartered accountant (ACA).

Dr. James Januzzi is the Hutter Family Professor of Medicine at Harvard Medical School, staff cardiologist at Massachusetts General Hospital, and Senior Cardiometabolic Faculty at Baim Institute for Clinical Research. His research spans all aspects of drug development, including contributions towards a deeper understanding of cardiac biomarker testing and effects of drug therapies for the treatment of patients suffering from heart failure, diabetes, and acute coronary syndromes.

He serves as a member of the Board of Trustees at the American College of Cardiology, and he is an Associate Editor at the Journal of the American College of Cardiology and the Journal of the American College of Cardiology: Heart Failure.

Dr. Januzzi is one of the most highly cited researchers in cardiology, having published more than 600 manuscripts, book chapters and review articles. He has edited textbooks on cardiac biomarker testing as well as the Massachusetts General Hospital Cardiology Review Book and has served on the ACC/AHA Heart Failure Guidelines writing committee. After medical school at New York Medical College in Valhalla, NY, he completed a residency in internal medicine at Brigham and Women’s Hospital, followed by fellowship in cardiology and cardiac ultrasound at Massachusetts General Hospital, where he joined the staff in 2000.

John Young most recently served as Group President and Senior Advisor to the Pfizer CEO prior to his retirement from Pfizer in mid-2022. He also serves on the Boards of Johnson Controls International (JCI), Novartis AG (NVTS) and Arvinas (ARVN). 

A scientist by training, John has almost 35 years of experience with Pfizer and has held several leadership positions across the organization. As Chief Business Officer, John led a division that integrated all Strategy, Consulting, Business Development, Business Assessment, Portfolio & Decision Analysis, and the Patient & Health Impact reimbursement and access teams. He also played an integral role in the collaborations that led to the successful development and delivery of the Pfizer-BioNTech COVID-19 vaccine. Prior to this role, John was the Group President of Pfizer Innovative Health, which included six business units: Internal Medicine, Inflammation & Immunology, Oncology, Rare Disease, Vaccines and Consumer Healthcare. Each business unit focused on developing innovative breakthrough medicines or vaccines, and on increasing access for patients impacted by diseases with significant unmet need. John holds a B.Sc. in Biological Science from Glasgow University and an MBA from Strathclyde Graduate Business School.

Anne Prener, M.D., Ph.D., has more than 25 years of leadership experience within life science companies. Anne joined Imbria Pharmaceuticals as Chief Executive Officer (CEO) in July 2020. Anne also serves as Venture Partner at SV Health Investors. Anne has led companies and teams across several therapeutic areas, including a focus on rare diseases. As CEO of Freeline, a liver-directed gene therapy company, she scaled the company from preclinical stage to a fully integrated biotechnology organization, which included a broad, internally developed pipeline, two programs in clinical development and a commercial-scale, high-quality CMC and manufacturing platform.

Prior to joining Freeline, she served as CEO of Gyroscope Therapeutics Ltd., a gene therapy company focused on eye diseases. Before that, Dr. Prener was Global Therapeutic Area Head of Hematology and Vice President, Clinical Research Hematology at Baxalta. During her time there, three new major product approvals in the U.S. and EU were secured along with a significant advancement in Baxalta’s hematology portfolio. Earlier in her career, Dr. Prener held several positions of increasing responsibility at Novo Nordisk, most recently serving as Senior Vice President, Hemophilia R&D Portfolio, where she was instrumental in building a portfolio of late stage and commercial hemophilia products. Dr. Prener serves on the Board of Directors of Galecto. She holds a Ph.D. in epidemiology and an M.D., both from the University of Copenhagen.

Nikola joined SV Health Investors in 2022 as Partner in their Biotech team. Previously, Nikola was a Partner at Pfizer Ventures, Pfizer’s corporate venture capital group. There he was responsible for investments in emerging companies developing transformative medicines spanning all therapeutic areas and modalities aligned with the future directions of Pfizer. In prior roles at Pfizer, Nikola was responsible for R&D technology investments, R&D strategy and early clinical portfolio management within the R&D organization. Nikola joined Pfizer from McKinsey & Co., where he served as an Associate Principal and senior member of the Pharmaceuticals Practice, advising top pharmaceutical, biotech, and healthcare companies on a range of strategy, corporate finance and commercial topics across geographies and therapeutic areas. Nikola received his PhD in Biochemistry and Molecular Biophysics from Columbia University and holds a Diplom in Biochemistry from Goethe University Frankfurt.